Protagonist Therapeutics (PTGX) Now Covered by Analysts at Stifel Nicolaus

Stifel Nicolaus assumed coverage on shares of Protagonist Therapeutics (NASDAQ:PTGX) in a report released on Monday, January 29th, Marketbeat.com reports. The brokerage issued a buy rating and a $32.00 target price on the stock.

Other equities analysts have also issued reports about the company. Zacks Investment Research raised Protagonist Therapeutics from a hold rating to a buy rating and set a $19.00 target price for the company in a report on Saturday, November 11th. BidaskClub raised Protagonist Therapeutics from a hold rating to a buy rating in a report on Friday, December 29th. Finally, BMO Capital Markets upped their target price on Protagonist Therapeutics from $40.00 to $43.00 and gave the company an outperform rating in a report on Tuesday, November 7th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of $32.50.

Protagonist Therapeutics (NASDAQ PTGX) opened at $17.50 on Monday. The stock has a market capitalization of $352.25, a P/E ratio of -6.51 and a beta of -0.80. Protagonist Therapeutics has a twelve month low of $8.00 and a twelve month high of $23.75.

In other Protagonist Therapeutics news, insider Richard S. Shames sold 3,529 shares of the stock in a transaction on Friday, December 22nd. The stock was sold at an average price of $20.50, for a total transaction of $72,344.50. Following the completion of the transaction, the insider now directly owns 3,529 shares of the company’s stock, valued at $72,344.50. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Dinesh V. Ph D. Patel sold 1,790 shares of the stock in a transaction on Wednesday, December 20th. The shares were sold at an average price of $19.55, for a total value of $34,994.50. Following the transaction, the insider now directly owns 192,227 shares of the company’s stock, valued at $3,758,037.85. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 15,944 shares of company stock valued at $319,839. 15.50% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Northern Trust Corp grew its holdings in Protagonist Therapeutics by 24.0% during the second quarter. Northern Trust Corp now owns 98,825 shares of the company’s stock valued at $1,118,000 after purchasing an additional 19,159 shares during the period. First Manhattan Co. bought a new position in Protagonist Therapeutics during the third quarter valued at $293,000. FMR LLC grew its holdings in Protagonist Therapeutics by 0.4% during the second quarter. FMR LLC now owns 2,528,462 shares of the company’s stock valued at $28,597,000 after purchasing an additional 10,264 shares during the period. Jennison Associates LLC bought a new position in Protagonist Therapeutics during the fourth quarter valued at $2,080,000. Finally, Alps Advisors Inc. bought a new position in Protagonist Therapeutics during the fourth quarter valued at $472,000. 42.45% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This story was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/02/15/protagonist-therapeutics-ptgx-coverage-initiated-at-stifel-nicolaus.html.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply